9/20/21 17:31 | 9/16/21 | CGEM | Cullinan Oncology, Inc. | | Health | BioPrd | Biological Products, (No Diag | Ubs Oncology Impact Fund L.P. | MA | T | | S | -91 | 29.06 | 0 | -3 | 0 | 7,648 | D | | | | | | | | | | | | | | |
9/16/21 16:45 | 9/14/21 | CGEM | Cullinan Oncology, Inc. | | Health | BioPrd | Biological Products, (No Diag | Ubs Oncology Impact Fund L.P. | MA | T | | S.m | -395 | 29.17 | 0 | -14 | 0 | 7,651 | D | | | | | | | | | | | | | | |
9/13/21 18:24 | 9/9/21 | CGEM | Cullinan Oncology, Inc. | | Health | BioPrd | Biological Products, (No Diag | Ubs Oncology Impact Fund L.P. | MA | T | | S.m | -680 | 29.23 | 0 | -23 | 0 | 7,665 | D | | | | | | | | | | | | | | |
9/8/21 18:20 | 9/3/21 | CGEM | Cullinan Oncology, Inc. | | Health | BioPrd | Biological Products, (No Diag | Ubs Oncology Impact Fund L.P. | MA | T | | S.m | -1,420 | 29.20 | 0 | -49 | -1 | 7,688 | D | | | | | | | | | | | | | | |
9/2/21 17:26 | 8/31/21 | CGEM | Cullinan Oncology, Inc. | | Health | BioPrd | Biological Products, (No Diag | Ubs Oncology Impact Fund L.P. | MA | T | | S.m | -717 | 29.50 | 0 | -24 | 0 | 7,737 | D | | | | | | | | | | | | | | |
8/31/21 16:47 | 8/27/21 | CGEM | Cullinan Oncology, Inc. | | Health | BioPrd | Biological Products, (No Diag | Ubs Oncology Impact Fund L.P. | MA | T | | S.m | -1,297 | 29.24 | 0 | -44 | -1 | 7,761 | D | | | | | | | | | | | | | | |
8/25/21 19:42 | 8/23/21 | CGEM | Cullinan Oncology, Inc. | | Health | BioPrd | Biological Products, (No Diag | Ubs Oncology Impact Fund L.P. | MA | T | | S.m | -3,101 | 29.29 | 0 | -106 | -1 | 7,805 | D | | | | | | | | | | | | | | |
8/12/21 16:55 | 8/11/21 | CGEM | Cullinan Oncology, Inc. | | Health | BioPrd | Biological Products, (No Diag | Ubs Oncology Impact Fund L.P. | MA | T | | S | -73 | 29.05 | 0 | -3 | 0 | 7,911 | D | | | | | | | | | | | | | | |
2/14/19 17:34 | 2/12/19 | HARP | Harpoon Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Ubs Oncology Impact Fund L.P. | MA | T | | S.d | -6 | 14.00 | 0 | 0 | 0 | 3,898 | D | | | | | | | | | | | | | | |